Incyte: Cheaper, Growing Faster, And The Market Keeps Paying Up For Amgen

In the world of biotech investing, paying more for less growth is a tough pill to swallow, yet that is exactly the proposition Amgen puts to its shareholders today.

In the biotechnology sector, investors are often faced with a choice between established scale and nimble growth. Amgen (AMGN) and its industry peer Incyte (INCY) put that choice in sharp relief. The market currently charges 20.9 times operating profit for Amgen, but only 14.0 times for Incyte, which has been growing its revenue faster. Over the past year, this valuation gap has widened significantly as investors continued to pay up for Amgen while Incyte’s multiple came down. That puts Amgen’s premium squarely on trial: what, exactly, does it still buy you?

Amgen’s Premium Is The Price Of A Diversified Growth Engine

With a market capitalization of about $238.9 billion, Amgen offers investors a stake in a global powerhouse. The defense of its premium starts with this sheer scale and the diversification it affords. Management recently noted that 17 of its products were annualizing at more than $1 billion in sales, a breadth that provides a buffer against the patent expirations and competitive pressures that can plague companies reliant on a single blockbuster.

This is not a legacy business coasting on old successes. Management points to its “6 key growth drivers,” a group of newer products that grew at an aggregate rate of 26% year-over-year and now represent nearly 70% of the company’s product sales. The premium also buys a ticket to a high-stakes, late-stage pipeline, including potential mega-blockbusters like the obesity asset MariTide and cardiovascular drug Olpasiran. This focus on the future pipeline is a key part of Amgen’s story, which some have called the price of a promise. Backed by this performance, the company raised its full-year 2026 revenue guidance to a range of $38.2 billion to $39.4 billion.

The key numbers side by side, today:

OpInc = Operating Income, P/OpInc = Price To Operating Income Ratio

And the same comparison exactly a year ago, so you can see which way the mismatch has been moving:

OpInc = Operating Income

Is Incyte’s Focused Growth Now Too Cheap To Ignore?

Paying for Amgen’s scale means forgoing the strong numbers at Incyte. The smaller peer grew revenue 26.9% over the last twelve months, far outpacing Amgen’s 9.1%. That faster growth comes at a significant discount, with an operating margin of 31.6% that is slightly ahead of Amgen’s 30.0%, suggesting efficient execution.

Incyte’s compressed, cheaper multiple belies a business with its own forward momentum. The company recently raised its forward guidance on total net sales, signaling confidence in its commercial portfolio. That confidence is underpinned by tangible progress, such as the recent European Union approval of Opzelura cream for atopic dermatitis, which opens a new front for growth. For investors who find the choice between the two difficult, a broader biotech ETF like IBB offers exposure to both companies and the industry as a whole.

The Decision Turns On Pipeline Promise Versus Proven Momentum

Ultimately, the choice between Amgen and Incyte is a choice between two different investment theses. Amgen’s premium buys a diversified, cash-flowing giant that is funding a pipeline with the potential to address some of the largest markets in medicine. Incyte offers faster current growth, positive business momentum, and a much lower valuation.

The question boils down to this: are you willing to pay up for the potential of Amgen’s large, but still unproven, late-stage pipeline, or do you prefer the cheaper valuation on Incyte’s demonstrated commercial success? The most important watchable for Amgen’s premium will be the clinical trial progress of its lead obesity asset, MariTide, which management describes as “fundamentally different” from other therapies. Its success or failure will be a major test of the long-term growth story you are paying for today.

Rather Compare Them On Your Own Terms?

You can line Amgen and Incyte up directly on the Amgen peer comparison, weigh them on valuation, growth, margins, and returns, and swap in any other Biotechnology names you hold.

Whichever Side You Pick, Pick A Process Too

Maybe the premium is earned; maybe the cheaper, faster grower is the smarter hold. Either answer still leaves you with a single stock’s risks: one product cycle, one management team, one industry’s weather.

The Trefis High Quality (HQ) Portfolio spreads that bet across roughly 30 quality businesses selected for consistent cash generation, strong margins, and resilient balance sheets, re-balanced by rules rather than conviction. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Decide the pair on the merits; let the portfolio carry the risk.